| Literature DB >> 35756779 |
Keigo Maeda1,2, Yuzo Hirai3, Masanori Nashi1, Shinsuke Yamamoto1, Naoki Taniike1, Toshihiko Takenobu1.
Abstract
Background/purpose: The epidemiology of infective endocarditis (IE) is under constant change due to the aging society and increases in antimicrobial-resistant pathogens. However, IE remains severe. This study aimed to review the current clinical characteristics of IE and the antimicrobial susceptibility of oral bacteria (OB) isolated from blood cultures to implement appropriate antimicrobial prophylaxis. Materials and methods: We retrospectively investigated the clinical features of 180 patients with IE in whom OB and pathogens except OB (eOB) were identified as causative microorganisms via blood cultures. The susceptibility of the OB group to eight antibiotics was examined by broth microdilution.Entities:
Keywords: Antimicrobial prophylaxis; Antimicrobial susceptibility; Dental procedure; Infective endocarditis; Oral bacteria
Year: 2021 PMID: 35756779 PMCID: PMC9201522 DOI: 10.1016/j.jds.2021.09.023
Source DB: PubMed Journal: J Dent Sci ISSN: 1991-7902 Impact factor: 3.719
Figure 1Causative microorganisms.
Clinical data of patients with infective endocarditis in the oral bacteria and excluding oral bacteria groups.
| eOB group ( | OB group ( | ||
|---|---|---|---|
| Age range (mean age), years | 6–92 (67.6 ± 17.9) | 20–93 (64.7 ± 18.6) | 0.1653 |
| Sex | 0.5643 | ||
| Male, | 77 (61.1) | 33 (61.1) | |
| Female, | 49 (38.9) | 21 (38.9) | |
| Cardiac condition, | 43 (34.1) | 29 (53.7) | 0.0113 |
| Valvular heart disease, including post-heart valve surgery | 33 | 24 | |
| Pacemaker implanted | 10 | 4 | |
| Ventricular septal defect | 2 | 3 | |
| Previous episode of IE | 2 | 0 | |
| Hypertrophic cardiomyopathy | 0 | 1 | |
| Bicuspid aortic valve | 1 | 0 | |
| Treatment of IE | |||
| Surgical treatment, | 51 (40.8) | 29 (51.9) | 0.0765 |
| Mortality, | 13 (10.3) | 0 (0) | 0.0080 |
eOB, excluding oral bacteria; OB, oral bacteria; and IE, infective endocarditis.
Antimicrobial susceptibility data.
| Susceptibility, % ( | ||
|---|---|---|
| Ampicillin | 98.0 (50/51) | |
| Penicillin | 98.0 (50/51) | |
| Ceftriaxone | 100 (51/51) | |
| Clarithromycin | 66.7 (16/24) | 0.0003 |
| Azithromycin | 60.0 (9/15) | 0.0003 |
| Clindamycin | 88.2 (45/51) | 0.0560 |
| Levofloxacin | 92.2 (46/51) | 0.1023 |
| Vancomycin | 100 (51/51) |
∗Differences between the antimicrobial susceptibility of clarithromycin, azithromycin, clindamycin, and levofloxacin and that of ampicillin were deemed significant at a p-value of <0.05.
Antimicrobial susceptibility to clarithromycin and azithromycin compared with that of clindamycin.
| Susceptibility, % ( | ||
|---|---|---|
| Clindamycin | 88.2 (45/51) | |
| Clarithromycin | 66.7 (16/24) | 0.0253 |
| Azithromycin | 60.0 (9/15) | 0.0127 |
∗Differences were deemed significant at a p-value of <0.05.